Protocol Design Featured Articles
-
New Calculator Could Help Trial Participants And Sponsors Determine Costs And Fair Compensation
12/14/2023
Try the industry’s first open access financial burden calculator to help patients, sponsors, and other stakeholders estimate the cost burden patients may face.
-
Trip Or No Trip: Pharmas Are Taking Psychedelic Trials To Australia
12/13/2023
Enveric Biosciences CEO Joseph Tucker, Ph.D., chronicles the company's quest for regulatory approval in Australia, as well as navigates the unknowns of developing psychedelics for therapeutic use.
-
Who Are Your TMF Customers? The Key To Greater Trial Efficiency & Quality
12/12/2023
Could your director of clinical operations or TMF manager identify all customers of the TMF? Perhaps not. Learn why knowing all customers is so important to efficient, high-quality trials.
-
A Primer For Understanding Psychedelic Clinical Research
12/11/2023
The emerging field of clinical research on psychedelics brings a unique and transformative approach to CNS drug development. Explore more.
-
Can Data Help Improve Diversity In Clinical Trials?
12/7/2023
Denise Bronner Ph.D., director of diversity, equity, and inclusion in clinical trials at Johnson & Johnson Innovative Medicine (JJIM) talks about some of the types of datasets that can be leveraged to improve diversity in clinical trials.
-
Q&A With Novartis And IQVIA Study Start-Up Leaders
12/6/2023
The industry is measuring longer cycle times between protocol approval and site activation. Experts from Novartis and IQVIA share creative solutions to combat this trend and accelerate trial timelines.
-
Identifying Digital Endpoints For Fatigue To Drive Better Clinical Care And Treatments
11/28/2023
The absence of clear biological indicators for fatigue makes diagnosing and finding effective treatments difficult. Cambridge Cognition's Michele Veldsman, Ph.D. is working to develop better biomarkers to improve diagnosis, care, and treatment.
-
Best Practices For Conducting Clinical Trials In Africa
11/21/2023
With its rich ethnic diversity, low trial density, and developing healthcare infrastructures, Africa is poised to become the next frontier of clinical research.
-
How Pfizer Prioritizes Diversity When Implementing Multiple Myeloma Trials
11/21/2023
Every patient deserves the chance to feel seen, heard, and prioritized in research and care — and for Black individuals with multiple myeloma, it’s a matter of urgency.
-
Trial Site Selection And Design Insights For Neurodegenerative Diseases
11/16/2023
Amylyx’s head of global clinical development Lahar Mehta, MD, talks multi-stakeholder trial design, purposeful site selection, the importance of caregiver burden, and the benefits of an open label extension (OLE).